Metro (MRU) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
4 Mar, 2026Executive summary
First quarter sales reached CAD 5.12 billion, up 2.9% year-over-year, with growth in both food and pharmacy segments; food same-store sales up 1% and pharmacy same-store sales up 5.1%.
Adjusted net earnings increased 4.4% to CAD 245.4 million, and adjusted EPS rose 7.8% to CAD 1.10; net earnings rose 13.6% to CAD 259.5 million.
EBITDA was CAD 481.5 million, representing 9.4% of sales, up 2.9% year-over-year.
Dividend declared at CAD 0.37 per share, a 10.4% increase from last year.
Strong performance attributed to revenue growth, expense control, and the successful launch of Moi Rewards in Ontario.
Financial highlights
Gross margin was 19.7% of sales, slightly up from 19.6% last year.
Operating expenses rose to 10.3% of sales, mainly due to the Moi Rewards launch and professional fees for tax resolution.
Net financial costs decreased to CAD 30.7 million, mainly due to interest receivable from a resolved tax file.
Effective tax rate dropped to 18.2% from 25% last year, reflecting a CAD 20.6 million tax gain and a CAD 6.1 million tax holiday.
Online food sales up 18.6%, driven by third-party partnerships and expanded click-and-collect services.
Outlook and guidance
Annual growth target for adjusted net earnings per share remains 8%-10% over the medium and long term.
Profit growth expected to gradually resume in fiscal 2025.
CapEx guidance remains at CAD 550-600 million for the year.
Focus on efficiency gains and improved service following major supply chain investments.
Latest events from Metro
- Q2 sales up 5.5%, adjusted EPS up 12.1%, net earnings up 17.6%, supply chain investments ongoing.MRU
Q2 20254 Mar 2026 - Sales up 3.5%, stable margins, but net earnings fell 14.6% amid automation costs.MRU
Q3 20244 Mar 2026 - Q4 saw higher margins, strong pharmacy and online sales growth, and a completed supply chain overhaul.MRU
Q4 20244 Mar 2026 - Q3 sales rose 3.3%, adjusted EPS up 12.6%, with strong pharmacy and discount banner growth.MRU
Q3 20254 Mar 2026 - Q4 sales and earnings rose despite supply chain disruptions, with a strong FY 2026 outlook.MRU
Q4 20254 Mar 2026 - Sales up 3.3%, adjusted EPS up 5.5%, net earnings down 12.8% on one-time costs; dividend up 10.1%.MRU
Q1 20264 Mar 2026 - Strong results, board re-elections, and strategic growth plans highlighted, with rising dividends.MRU
AGM 20259 Jan 2026